These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15233293)

  • 21. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases.
    Lacroix H; Iglehart JD; Skinner MA; Kraus MH
    Oncogene; 1989 Feb; 4(2):145-51. PubMed ID: 2564657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastric carcinoma: expression of c-erbB-2/neu oncoprotein, epidermal growth factor receptor, cathepsin D, progesterone receptor and tumor associated glycoprotein-72 in different histological types.
    Peláez Buján Mdel C; Ruibal Morell A; Aza González J
    Rev Esp Enferm Dig; 1999 Dec; 91(12):826-37. PubMed ID: 10619912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
    Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
    Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas.
    Busam KJ; Tan LK; Granter SR; Kohler S; Junkins-Hopkins J; Berwick M; Rosen PP
    Mod Pathol; 1999 Aug; 12(8):786-93. PubMed ID: 10463481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma.
    Pryczynicz A; Guzińska-Ustymowicz K; Kemona A; Czyzewska J
    Anticancer Res; 2008; 28(2B):1399-404. PubMed ID: 18505086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients.
    Florena AM; Tripodo C; Guarnotta C; Ingrao S; Porcasi R; Martorana A; Lo Bosco G; Cabibi D; Franco V
    Pathobiology; 2007; 74(6):317-22. PubMed ID: 18087195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
    Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
    Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
    Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
    Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The relationship between expression of interleukin-8 and prognosis of breast cancer].
    Yao C; Wang SM; Xie D; Wu HX; Chen DY; Lin Y
    Zhonghua Wai Ke Za Zhi; 2006 Jul; 44(13):900-3. PubMed ID: 17067482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions.
    Meert AP; Martin B; Verdebout JM; Feoli F; Mascaux C; Ninane V; Sculier JP
    Anticancer Res; 2006; 26(1A):135-8. PubMed ID: 16475689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.
    Jalava P; Kuopio T; Huovinen R; Laine J; Collan Y
    Anticancer Res; 2005; 25(3c):2535-42. PubMed ID: 16080489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation of expression of epidermal growth factor receptor-2 expression and tumor marker p53 in primary breast cancer].
    Liu P; Liu Y; Zhang J
    Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1844-7. PubMed ID: 17922997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.